Pilocarpine (Imidazole Alkaloid · Glaucoma · Xerostomia · Informational Reference)

Compound	Pilocarpine
Chemical class	Alkaloid — Imidazole (Ethyl imidazole alkaloid; from jaborandi)
CAS	92-13-7
Primary source	Pilocarpus jaborandi (jaborandi), Pilocarpus microphyllus (leaves)
Key applications	Pharmaceutical: glaucoma (ophthalmic), xerostomia/Sjögren’s syndrome (oral); parasympathomimetic; informational reference
Claim strength	High (as pharmaceutical); Informational only
Typical form	Ophthalmic solution (Isopto Carpine); oral tablets (Salagen); not a dietary supplement
Buy from Herbuno	Browse HerbIQ Compound Index →

Name origin: From Pilocarpus (the genus, from Greek pilos = felt cap, referring to the leaf shape). Pilocarpine is an imidazole alkaloid — the imidazole ring distinguishes it from most other alkaloid classes and is the pharmacophore responsible for muscarinic receptor binding. Traditional use and discovery: Jaborandi leaves (Pilocarpus jaborandi) have been used by indigenous peoples of Brazil and the Caribbean for their profuse salivation-inducing properties (the name “jaborandi” comes from Tupi words meaning “what causes slobbering”). Brazilian physician Ezequiel Corrêa dos Santos introduced jaborandi to European medicine in 1873; pilocarpine was isolated shortly after. Nantes ophthalmologist Louis Weber observed its intraocular pressure-lowering effect in 1875 — establishing pilocarpine as the first effective glaucoma treatment. Current pharmaceutical status: Pilocarpine is a WHO Essential Medicine for: (1) ophthalmic glaucoma treatment (eye drops, reducing intraocular pressure via trabecular meshwork enhancement and ciliary muscle contraction increasing aqueous humour outflow); (2) oral treatment of xerostomia (dry mouth) in Sjögren’s syndrome and post-radiation therapy (salivary gland stimulation via muscarinic M3 activation). Supplement status: Pilocarpine is a pharmaceutical drug with significant parasympathomimetic effects; not a dietary supplement ingredient.

---

Pilocarpine — Pharmaceutical Context

Glaucoma treatment mechanism: Pilocarpine is a muscarinic M3 agonist. In the eye, M3 activation contracts the ciliary muscle, pulling the trabecular meshwork apart and enhancing aqueous humour outflow — reducing intraocular pressure (IOP). It also constricts the pupil (miosis), which may relieve angle-closure glaucoma by pulling the iris away from the drainage angle. Pilocarpine was the dominant glaucoma treatment before the development of beta-blockers (timolol), prostaglandin analogues (latanoprost), and carbonic anhydrase inhibitors. Modern glaucoma management uses these newer agents; pilocarpine retains use for angle-closure glaucoma and as adjunctive therapy. Pharmaceutical evidence: High.

Xerostomia and Sjögren’s syndrome: Oral pilocarpine (5 mg three times daily) is approved for treatment of xerostomia (dry mouth) caused by salivary gland hypofunction in Sjögren’s syndrome (autoimmune salivary/lacrimal gland damage) and post-radiotherapy for head and neck cancer. Multiple RCTs confirm significant improvement in saliva flow and subjective dry mouth scores. M3 receptor stimulation directly activates salivary gland secretion. Pharmaceutical evidence: High.

Presbyopia treatment (novel ophthalmic): Vuity (pilocarpine 1.25% ophthalmic solution) was FDA-approved in 2021 for presbyopia (age-related loss of near-vision accommodation) — pilocarpine’s pupil-constricting effect improves depth of focus. The first approved pharmacological treatment for presbyopia. Pharmaceutical evidence: High (pivotal RCT data).

---

Frequently Asked Questions — Pilocarpine

What are the side effects of pilocarpine?
Pilocarpine’s muscarinic M3 agonism produces classic parasympathomimetic effects at systemic doses: sweating (the most common side effect with oral pilocarpine, reported in ~40% of patients), flushing, urinary frequency, GI cramping, and rarely bronchospasm. Ophthalmic pilocarpine eye drops produce local effects (miosis, accommodative spasm causing temporary blurred vision, headache) with minimal systemic absorption at recommended doses.

Can pilocarpine help with dry eyes as well as dry mouth?
Yes — oral pilocarpine stimulates all exocrine glands via M3 receptor activation, including tear glands (lacrimal glands). In Sjögren’s syndrome (where both salivary and lacrimal glands are damaged by autoimmune attack), oral pilocarpine provides symptomatic benefit for both xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes). This dual benefit is well-documented in the pilocarpine Sjögren’s clinical trials.

Is jaborandi used in traditional medicine for anything besides salivation?
Brazilian traditional medicine uses jaborandi preparations for rheumatic conditions, urinary problems, and skin conditions — though these applications are not well-studied. The primary documented and commercially relevant traditional use is pilocarpine’s diaphoretic (sweating-inducing) and sialagogue (saliva-inducing) properties, which align precisely with its muscarinic M3 pharmacology. Jaborandi was also historically used by Brazilian healers for fever management — the sweating effect providing symptomatic relief via evaporative cooling.

Are there plant-derived alternatives to pilocarpine for salivary stimulation?
Cevimeline (Evoxac) is an oral muscarinic agonist approved for Sjögren’s xerostomia with higher M3 selectivity and longer half-life than pilocarpine — but it is also a synthetic pharmaceutical, not a botanical. For mild dry mouth not associated with autoimmune disease, non-pharmacological approaches (hydration, sugar-free gum stimulating mechanical saliva release) and over-the-counter saliva substitutes are recommended. No botanical substitute for pilocarpine’s salivary gland M3 activation is established in clinical practice.

Related compounds: Arecoline, Vasicinone, Conessine, Nicotine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery